Stock Track | Alvotech Plunges 7.28% in Pre-market on Q1 Earnings Miss and Revenue Decline

Stock Track05-07

Alvotech's stock experienced a significant pre-market plunge of 7.28% on Thursday. This sharp decline follows the company's release of its first-quarter 2026 financial results after the market close on Wednesday.

The biotechnology firm reported revenue of $105.9 million for Q1 2026, representing a 20.3% decrease compared to the same period last year and falling well short of analyst expectations of $140.85 million. Earnings per share came in at breakeven, missing the consensus estimate of 2 cents per share.

CEO Lisa Graver attributed the weaker performance to a production slowdown related to facility improvements, which impacted both revenues and EBITDA. The company maintained its full-year guidance, but investors reacted negatively to the quarterly miss, extending losses from the post-market session into pre-market trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment